Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04875611 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment

Study acronym: NIVONASO-21
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 24, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Sep 30, 2023 to Dec 31, 2025
    • Start date changed from estimate of Jun 30, 2021 to Aug 26, 2021
    • Site details revised at 4 of 4 sites
    v3
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy . Patients disqualified from radical therapy . The total number of patients was estimated for 32.
Trial Details
NCT Number NCT04875611
Lead Sponsor Maria Sklodowska-Curie National Research Institute of Oncology
Collaborators: KCRI
Conditions
(from sponsor)		 Nasopharyngeal Cancer
Related terms Nasopharyngeal Neoplasms
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov